Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 19;2:5. doi: 10.1186/s40959-016-0014-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Barros-Gomes et al. 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Type I and Type II cardiotoxicity. Baseline and serial evaluation in patients receiving combined therapies with drugs with both type I and type II toxicity risk. Echocardiogram and cardiac biomarkers are performed during baseline. For abnormal baseline screening, we suggest cardio-oncology consultation. For normal baseline screening, we suggest serial monitoring with echocardiogram and biomarkers every 3 months during therapy and 6 months after completion of treatment. F/U indicates follow-up; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; cTn, serum cardiac troponin